Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neena Brizmohun

Neena Brizmohun writes and commissions news, features and analysis to meet the regulatory, business and market access information needs of the companies and regulatory agencies that operate in the pharmaceutical and medical device space worldwide.

Her areas of expertise include the cutting-edge early market access schemes that are being trialed around the world for taking drugs and medical devices to market faster. She is also interested in initiatives for harmonizing regulations at the global level as well as issues affecting clinical trials, manufacturing and post-market safety monitoring. She explores the challenges and opportunities that these issues introduce for both industry and the regulators and is on a constant look out for what might be coming next.

A scientist by training, Neena started her journalistic career at Informa in 1997. She has been the deputy editor of Scrip Regulatory Affairs since 2007. Prior to that, she worked as the science editor for Clinica Medtech Intelligence. Before becoming a journalist she worked as a biomedical scientist at St Thomas' Hospital in London for 10 years.

Latest From Neena Brizmohun

Triple-Negative Breast Cancer First In England As NICE Reverses Tecentriq Rejection

Roche has resolved the issues raised by the health technology assessment body over what is the first immunotherapy approved  for treating this aggressive and difficult-to-treat form of breast cancer.

Health Technology Assessment United Kingdom

Australia Fast-Tracks Over 40 COVID-19 Tests; Concern Emerges Over Sensitivity Claims

The country's Therapeutic Goods Administration has explained how sponsors can apply for expedited approval of tests for COVID-19 and what special conditions apply. Meanwhile, post-market reviews of two approved serology-based COVID-19 point-of-care tests suggest they are not as sensitive as their manufacturers had claimed.

Australia Coronavirus COVID-19

EMA’s Rasi: Approval Decision For Remdesivir May Come ‘Very Soon’

Speaking at a high-level European Parliament committee meeting today about COVID-19, the European Medicines Agency’s executive director indicated that Gilead would be submitting a conditional marketing authorization application for remdesivir in the EU.

Coronavirus COVID-19 Europe

Funding Wins For Lorviqua & Gazyvaro In England

Pfizer has dropped the price it was asking for Lorviqua, and evidence from the Cancer Drugs Fund appears to support the clinical trial evidence for Roche’s Gazyvaro.

Health Technology Assessment United Kingdom

New Filings At The EMA

New medicines under evaluation at the European Medicines Agency.

Drug Review Europe

England’s NICE Says Yes To Kadcyla In Early Breast Cancer

There is an unmet clinical need for an additional adjuvant therapy for people who have residual disease after neoadjuvant therapy, says health technology assessment body NICE.

Health Technology Assessment United Kingdom
See All
UsernamePublicRestriction

Register